First AD

Second AD

Breast cancer experts discuss the evolution of HER2-targeted treatments, including margetuximab, trastuzumab, tucatinib, and neratinib, along with unmet needs in patients with 

Breast Cancer

 Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

HER2+ Breast Cancer

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

Current Treatment Landscape for HER2+ Breast Cancer